We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+35.45%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.39B
AUM Growth
+$291M
Cap. Flow
+$36.6M
Cap. Flow %
2.63%
Top 10 Hldgs %
62%
Holding
63
New
10
Increased
3
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$139M
2
GTH
Genetron Holdings Limited ADS
GTH
+$85.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.9M
4
IMVT icon
Immunovant
IMVT
+$17.1M
5
KURA icon
Kura Oncology
KURA
+$15.1M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$37.8M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$32.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$28.2M
4
LITS
Lite Strategy Inc
LITS
+$26.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.39%
2 Financials 8.49%
3 Materials 3.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$266M 19.06%
1,797,745
-205,402
-10% -$28.2M
LEGN icon
2
Legend Biotech
LEGN
$3.68B
$151M 10.85%
+3,555,007
New +$139M
NFH
3
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$118M 8.49%
14,300,000
– –
GTH
4
DELISTED
Genetron Holdings Limited ADS
GTH
$76.5M 5.49%
+2,113,287
New +$85.7M
PASG icon
5
Passage Bio
PASG
$14.7M
$60.9M 4.37%
111,479
– –
AMRS
6
DELISTED
Amyris Inc.
AMRS
$43.5M 3.12%
10,181,472
+3,689,225
+57% +$12.3M
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.88B
$40.6M 2.91%
2,316,628
-1,004,173
-30% -$17.1M
ARQT icon
8
Arcutis Biotherapeutics
ARQT
$3.55B
$39M 2.8%
1,289,360
-397,167
-24% -$11.5M
SVA
9
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 2.74%
5,900,000
– –
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$30.4M 2.18%
+5,966,527
New +$24.9M
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$6.11B
$29.3M 2.1%
1,151,622
+392,572
+52% +$8.2M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$28.5M 2.04%
3,526,093
-49,331
-1% -$435K
KDMN
13
DELISTED
Kadmon Holdings, Inc.
KDMN
$27.4M 1.96%
5,347,768
-7,191,747
-57% -$32.2M
ZYME icon
14
Zymeworks
ZYME
$1.66B
$26.5M 1.9%
734,161
-367,075
-33% -$13.5M
ARWR icon
15
Arrowhead Research
ARWR
$12.1B
$24.9M 1.79%
576,505
-192,169
-25% -$6.78M
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$23.2M 1.66%
1,917,074
– –
CLDX icon
17
Celldex Therapeutics
CLDX
$2.79B
$20.8M 1.49%
+1,600,000
New +$7.09M
IMVT icon
18
Immunovant
IMVT
$7.99B
$19.5M 1.4%
+800,000
New +$17.1M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$343M
$18M 1.29%
860,648
– –
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
$17.9M 1.28%
1,476,796
– –
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$17.8M 1.28%
658,523
-230,201
-26% -$6.35M
EIGR
22
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$17.2M 1.23%
59,709
– –
KURA icon
23
Kura Oncology
KURA
$826M
$17.1M 1.23%
+1,050,000
New +$15.1M
CDXS icon
24
Codexis
CDXS
$136M
$17M 1.22%
1,493,903
– –
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.3M 1.1%
158,310
-175,311
-53% -$14.6M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Vivo Capital held 63 positions worth $1.39B, up 26% from $1.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vivo Capital's Q2 2020 filing shows 10 new, 3 increased, 21 reduced and 9 closed positions. Its largest new stake was Legend Biotech: 3,555,007 shares worth $151M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q2 2020 buy was Legend Biotech: 3,555,007 shares worth $151M.
  • Vivo Capital added most to Amyris Inc. in Q2 2020, an estimated $12.3M increase.
  • Vivo Capital's biggest Q2 2020 reduction was Kadmon Holdings, Inc., cutting an estimated $32.2M.
  • Vivo Capital fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $37.8M.
  • Vivo Capital's ten largest holdings make up 62% of its $1.39B portfolio in Q2 2020.
  • Vivo Capital opened 10 new positions and closed 9 in Q2 2020.
  • Vivo Capital's portfolio value rose 26% quarter-over-quarter to $1.39B.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.